Nvidia Reports Results… And A Big Move In The Pharma Space 2/26/25

26 Feb 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" - Nvidia Reports Results… And A Big Move In The Pharma Space

Air Date: February 26, 2025 Host: Melissa Lee Guests: Tim Seymour, Steve Rosso, Dan Nathan, Guy Adami

Episode Overview In this episode, the traders analyze Nvidia's recent earnings report, its impact on the AI market, and the significant rise in Madrigal Pharma's stock following positive trial results. Additionally, General Motors announces a dividend increase and a substantial stock buyback, sparking discussions on its stock performance.

Segment Breakdown

Nvidia Earnings Report

  • Performance: Nvidia reported better-than-expected sales and profits, generating significant volatility in its stock price.
  • Key Metrics:
  • Revenue and profit exceeded estimates, but growth is reportedly slowing.
  • Guidance was set above Wall Street expectations at $42 billion.
  • Data centers account for over 80% of Nvidia's revenue, with the Blackwell product line achieving $11 billion in revenue, the fastest product ramp in the company's history.
  • Margins and Competition:
  • Gross margins were lower than expected (71% vs. anticipated 73%).
  • Concerns were raised about the potential for margins to decline further, impacting future performance.
  • Discussion on competition from peers such as AMD and Intel, with Nvidia maintaining a dominance in the market.

Market Reactions

  • Traders’ Opinions:
  • Some traders expressed skepticism regarding Nvidia's future growth potential, particularly in the face of slowing demand from hyperscalers.
  • Others highlighted Nvidia's relative value in comparison to peers and its continued leadership in the AI sector.
  • Key Questions Raised:
  • What will be the catalyst for Nvidia’s stock to reaccelerate?
  • Is there a risk of revenue decline if major customers cut back on spending?

General Motors Updates

  • Corporate Actions:
  • GM announced a 25% increase in its quarterly dividend and a $6 billion stock buyback program.
  • Market Performance:
  • Shares rose nearly 4% following the announcement.
  • Traders’ Analysis:
  • Discussions focused on GM's profitability and future prospects, emphasizing that dividends and buybacks could positively influence stock valuation.

Madrigal Pharma Surge

  • Performance Highlights:
  • Madrigal's stock surged following strong Q4 results driven by its MASH fatty liver disease drug, Resdifera.
  • The company reported improvements from clinical trials, positioning it favorably in the competitive landscape of liver disease treatments.
  • CEO Insight:
  • CEO Bill Sibble discussed the drug's market penetration and the positive impact of competing therapies on awareness and prescribing behavior.

Key Takeaways

  • Nvidia's Future Outlook: The company faces challenges with margin pressures and competitive threats, despite its strong market position in AI technology.
  • GM's Strategic Moves: GM's actions reflect confidence in its financial health and commitment to returning capital to shareholders.
  • Madrigal’s Growth Potential: The positive trial data and market response suggest significant upside potential for Madrigal Pharma as it captures a larger share of the liver disease treatment market.

Conclusion The discussions in this episode highlight significant movements in the semiconductor and pharmaceutical markets, alongside a focus on corporate strategy within the automotive sector. The traders offered diverse perspectives on the implications of Nvidia's financials, GM's corporate actions, and Madrigal's promising drug trial results, painting a comprehensive picture of current market dynamics.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00Live from the Nasdaq market side in the heart of New York City's Times Square this is Fast money. Here's what's on tap tonight. NVIDIA on the move. Shares just turning higher after being sales and profit estimates. What is driving the volatility and what could it mean for the AI trade? Plus, magical madrigal. Shares of the pharma company hitting more than 12-year highs on the back of its results. The CEO will join us for more on the latest trial data and what's next for the name. And revving up, GM upping its dividend and buying back billions in stock. Is it enough to keep shares accelerating?

0:30How the traders are playing the auto giant right now. I'm Melissa Lee, coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Steve Rosso, Dan Nathan, and Guy Adami. We start off with an earnings alert on NVIDIA shares of the AI chipmaker volatile after its results. It's currently up at 2.6%. The conference call just kicking off. Let's bring in CNBC's Christina Parsnettles for more on the quarter. Christina. Well, you mentioned it. They beat on both revenue and profit, but growth is slowing. The guidance still came in above Wall Street expectations as well as buy-side expectations of$42 billion.

1:01That was a key number. Data centers remain NVIDIA's cash cow, generating over 80 percent of revenue. CFO Colette Kress noted they delivered$11 billion of Blackwell. That's the latest iteration of their, you can call it the architecture, GPUs, etc., data center products in Q4. And that's their fastest product ramp ever. It's also the first time we're actually getting a Blackwell number. CEO Jensen Wong in the actual press release saying AI is advancing at light speed, which may be easing some concerns about supply issues and show that demand fundamentals are still in play. But with the launch of new chips comes pressure on Q1 margins coming in below analyst expectations at 71 percent.

1:38Management had previously warned on the earnings call the last two quarters that margins would dip before recovering to mid 70s. So I think 75 percent in the second half of this year. You talked about shares first. They were up. Then they were down. It's the most active member of the Nasdaq 100, followed by Tesla at the moment. Melissa, Christine, I'm curious on the Blackwell revenue number. Was there a street consensus estimate for that? Was$11 billion sort of in line, or do we not know that? I only have it for data center, not specifically for Blackwell. For Blackwell. Okay. Christina, thanks.

2:09Christina Parts Nevelis. I ask that only because Blackwell has a higher margin than its other chips. But Guy, what do you make of the quarter? So last night, Gene was on, Gene Munster. He thought they'd beat by$2 billion and then guide higher by$2 billion. So they beat by about a little over a billion. Let's call it a billion and a half. So that was light. And the guide was a little bit light. And it's not an indictment. It's just not what Gene thought. But the one number that stuck out to me, Christina just mentioned, gross margins are starting to go, I think, the wrong way. Now, the stock is up.

2:36That's fine. There's nothing to not like about the quarter other than the fact that if margins start to decelerate, that's when these stories typically get long in the tooth. So that's the one thing that I'm watching here. Yeah, you've got to watch because they said they're going to accelerate, re-accelerate in the back half of the year, so 75%. So you've got to think about what does that mean for competition? that means they're going to have more pricing power or, to your point, they're not going to break out Blackwell right now, but that should be a higher margin ramp. I just think of the trade, and we talk about it all the time, like, has it stalled out?

3:04Well, NVIDIA hasn't gone anywhere in eight months. You know, if you look at Microsoft, Google, Amazon, they're all down about 10 % from their recent highs, some more than that. So the trade, and Taiwan Semi, I'll throw in there, the trade, for all intents and purposes, has stalled out. So what is going to be the catalyst, I think, to get it reaccelerated? I'm not so sure right now because I can't imagine on a sequential basis that NVIDIA is going to be able to kind of do better than they just did. And what they just guided revenues to up or down 2 % from here. I mean, maybe that's an easy thing for them to beat, but it's going to have to be a big beat to get the stock going back towards new highs.

3:36You mentioned the nine-month time frame. I mean, it's not pre-DeepSeek. I mean, DeepSeek was a real setback in terms of it trying to make some ground up. Yeah, although, you know, we've got a 30 % guide on CapEx for hyperscalers. I'm less worried about DeepSeek than I might be about where we're talking about this. But the question is, if the company's not expensive now, and that's maybe open for debate, but to me, trading at a discount to peers at 31 times, 32 times with a peer group that's probably 33, 34, nobody's even close. So in a world where, okay, NVIDIA relative to themselves and relative to the last two years, this is one of the greatest bars to have to heat.

4:09This would be a Fosbury, Dick Fosbury, by the way. He was a fan of the show. He passed away. Fosbury flop. Fosbury flop. But but again, a really respected guy and a big fan of the show. But the bottom line here is you've got a case where AMD is doing nothing. They've told you half over half. There's there's very little growth there. NVIDIA continues to extend its lead. It's a case where, to me, that's really the story. If you're worried about the secular trends in AI, OK. But if you're worried about NVIDIA relative to anyone else in the world, it's not even close. And to me, the stock's not expensive.

4:44So it was so I would just say, I wouldn't say oversold. I would just say the negativity going to this print was reasonably high. And to me, this is a bit of a relief. So I'm going to take the other side of that, only because I think the stock price looks like it's it's rolling over and their revenues are reliant on the four top hyperscalers. It's 46 percent of their revenue. If this price, if they cut back a little bit on that deep seek headline. So there's deep seek doing it for 5 million. Was that the number? It's a lot less. Let's just say it's 5 billion. I think it was 5 million. Let's just say it's a lot less.

5:24There's a lot of middle ground. So even if that deep seek was a lot of nonsense, people are going to start to think I can do this on the cheap. And maybe I don't need a Blackwell. Maybe I don't need a large language model. Maybe I just need a chip. So why not pick out an AMD or an Intel? Intel's up 17%. I get it. It's the sum of the parts that had Intel running this year. But when you look at NVIDIA, if two of those four cut back, you could see a revenue decline of 23%. We've already heard the hyperscalers confirm, to Tim's point, confirm their annual CapEx intentions. What are we worried about here?

6:07Well, we're not worried about anything in the near term. We're not worried about demand. And we're now not worried about supplies. So, again, if you get back to a stock that there's no disputing. Disputing. This has been a dead trade. No one needs to point this out. This has been obvious. And in fact, it's underperformed its peer group. It's underperformed the SMH by about 11 % since their last earnings. But you get back to there's a big argument out there that even in a post-deep seek world, that the demand story even increases and the elasticity of demand outstrips even the fall on the prices.

6:33That's the argument. And when Intel is nowhere even on the playing field right now and AMD isn't even close, NVIDIA is still the one that they're getting even their lower-priced chips from. So just just one little bow on this. So if you look at chips or what supply demand. Right. So you if now you have to if you have too much or you have enough, that's a glut. It's a commoditized pricing. They have to the guy where he kicked it off. Gross margins have to continue to come in. So for me, I don't see prices increasing. I don't see the price of the stock increasing. And I'm not fighting, you know, on the price level of stock.

7:10Like Tim said, it looks like it's rolling over. I think you're going to see much lower prices for NVIDIA. Listen, there's lots of puts and takes here. You could say Stargate. You could say there's a whole host of meta building out a new project. There's a whole sovereign. There's a whole host of things you could say. Maybe we're just getting started, right? This has been a digestion phase as far as the spend. Now we start to think about what inference looks like and what is applications being built on all this stuff and what is the adoption for a whole host of us. That's going to be the next step.

7:38When it starts, who knows? The flip side of that is Anthropic. This is one of OpenAI's biggest competitors. They have this Claude model. They just released a new one, 3.7. Supposedly, that one was traded on tens of millions, not billions or anything like that. So there's something for everybody. You know, DeepSeek has been widely explained as not that negative for an NVIDIA right here, right now. And so, you know, again, I just think there's a little something for everybody. But I just don't think this is going to establish a new range. I don't think we're going to have another leg higher anytime soon in this trade.

8:10In the context, though, of market psychology at this point in time, I mean, how is this going to be perceived? The puts and takes, is it going to be perceived positive or negative? Are you going to glass half full or glass half empty at this point? Because I would say glass half empty. What's that diagram? When dog goes one way, the other goes. Oh, not the Venn diagram. We all know what that is. When you can see one thing or the picture. Horshack. Or the dress. The dress. Do you see gold or do you see blue? That was a few years ago. Okay. You all know what I meant, by the way. TD was saying that Microsoft canceled a bunch of data center capacity leases.

8:45And the market's freaked out. I think the market, this is a sigh of relief, I think, in terms of the after. So I think in terms of the broader market, you know, we'll just focus on the things that we're concerned about. This sort of gets us through, I think, in terms of the concern about NVIDIA. However, and Tim is right to point out, on a price to earnings, the stock is cheap compared to where its peers trade and really compared to where it should be trading. If you think about the head start, the problem, I think, is price to sales is still expensive. And if margins come down, that price to earnings goes up very precipitously.

9:15So that's been my concern. Now, the market isn't worried about it, clearly. But again, margin deterioration leads to an acceleration of P.E. All right. For more on NVIDIA, let's bring in Susquehanna senior analyst Chris Rolland. Chris, great to have you with us. What's your take on the quarter and what's your take on that$11 billion Blackwell revenue number? Yeah, I thought it was fine. $11 billion for Blackwell. We were thinking it was going to be five or six. So this is a very healthy, good number. We were worried about the April quarter as it's kind of this hole in revenue between Hopper and GB200.

9:52So we think this is a fine result. What are you looking for on the conference call, Chris? What's going to be your first question, if you have that first question? If I have that first question, it's going to be around GB200, whether system developers are ready to go, and when can we really ramp this product? Chris, cut to the chase on the hyperscaler. Excuse me, CapEx intensity. Where are you on this? Yeah, CapEx is going up. We were thinking growth was about 20 % across those hyperscalers you talked about going into the quarter. Coming out of the quarter, it looks like it's more like 30 % year over year.

10:33So this number is going up on the back of AI. Real quick, Chris, given the beat in Blackwell, and as Mel said earlier, the higher margin chip theoretically, wouldn't you expect to see margins hang in there actually be better than expected or am I way off base? You can tell me I am because that's typically the case. Yeah, you're not off base, but the company has very well telegraphed and communicated that gross margins during this Blackwell ramp were going to be low. And so for whatever reason, the street was modeling closer to 73%. That was off. It should have been closer to that 71%. So this is exactly as the CFO has, in fact, telegraphed.

11:22Chris, as you talk to investors, I'm just curious where there is skepticism. We were talking about how the stock has really not done too much over the past nine months. Is there skepticism around the forecast of hyperscalers that they're actually going to stick with those raised guidance numbers throughout the year? I mean, where is sort of the question marks? Where do they focus on? Yeah, I think there was some turbulence around DeepSeek. We're still trying to figure out efficiencies that came from that model and whether it decreases total spend or not. I think that's of less concern now, certainly, than it was a month ago.

12:01But really, people want to know timing around GB200. This is supposed to be the big product, not B200. It's GB200, racks of 72 GPUs. And it seems like these are coming a little bit later. Are there still problems? Are there still problems with liquid cooling? there's a lot of stuff that are going to come into these complicated systems and are they ready to go in time and if not is there a small hole in revenue in between and so that I think is probably the biggest concern for investors right now. So where do you want to see that launch Chris in the year? So I want to see it coming after the April quarter so their July quarter and I want to see it in earnest.

12:49Okay. Chris, we're going to leave it there. Thanks, as always, for your analysis on the heels of these numbers. And do not miss a CNBC special report on NVIDIA's results. John Fort will be speaking with CEO Jensen Huang about the numbers, his AI strategy, and more at 7 p.m. Eastern time right here on CNBC. So there's still a big question mark about an even bigger product than Blackwell to come potentially in the July quarter. Sure. Ruben, I can't wait. You know, Well, here's the thing. Tomorrow night, we're going to get Dell, right? So Dell makes the servers that a lot of these GPUs go into, that a lot of these servers go into the data center.

13:22So it'll be really interesting to see what they have to say. They've been growing kind of quickly when they reported in November. It was disappointing. I mean, PCs are not particularly great. We know that end market is really bad. So it'll be interesting to see what they have to say on servers tomorrow night. So this thing, we're all waiting for NVIDIA. It was a big nothing. You know, we've been waiting for like two months now. And so now we're going to put some other pieces of the puzzle together. Tim, famous Rubens for 500. Reuben Kincaid. Of course, you have to go Reuben Kincaid. Even I know Reuben Kincaid.

13:48Well, not my favorite sandwich. It's very greasy. Very greasy. Reuben Sierra actually had a pretty nice run with the Yankees. Reuben Kincaid. Do you have any salient points to make? Not particularly. I mean, but this is what happened last quarter as well, if you recall. There was no movement in the stock. The next day it made a new all-time high and then closed precipitously lower, had this engulfing pattern. So we'll see how it plays out over the next 24 hours. Might I also say that Jensen Huang is a master at speaking to the markets, speaking to investors, delivering what they want to hear. And John Ford's going to be speaking to him tonight at 7 o 'clock on CNBC.

14:24And the picture might not only change on the conference call, which is going on right now, but also change on the heels of this interview. It's going to be a fascinating interview. It's probably a must watch because I think the dynamics on sewing some of these pieces of uncertainty together, certainly I think the message is going to be positive. I think for the markets, this is positive. I think this was an overhang. I think this was something the markets wanted to get through. I mean, think of the price action. Think of also where Options Expring was on Friday. And a lot of people were betting against things getting kind of ugly into this print.

14:52There's all kinds of stuff going on around it. Well, let's talk about the context of the markets because we snapped a losing streak today. The S &P as well as the NASDAQ. You're ending a four-day losing streak. So what does this do? You were saying that this is a sigh of relief. Yeah, I think so. So, I mean, again, I think you've got a case where if you look how mega cap tech has been underperforming and there's been a bit of an indictment against all the cap spending against all the hyperscalers. So if we get reaffirmation that this is money well spent, I'd see meta turning around most immediately.

15:22So people, you wanted to see a rebound here and you and the market can't really do anything without Max 7. We've seen the equal weight outperform. We've seen Russell outperform. But when you look at the names that people hold the most of in their portfolios, it's these MAC7 names. People wanted to see them bounce. They got flushed out. RSIs dipped. I think you give it a couple of days, and I think you see this group probably roll over again. Give it a couple days, and you get PCE on Friday morning. And I think it's going to be really interesting to see where the 10-year yield has gone over the last few weeks from 4.8 % to 4.3%.

15:54Let's see if that's a hot number. We've seen some hot prints over the last few weeks or so. And I think that put and take. You want hot? I love that. Seriously, do you want hot? I honestly don't know. What's the game guy that we play every once in a while on this show? If you do. We're going to tell you what happened. We play a lot of games. I'm trying to think of which one applies in this case. It's definitely not traded or failed. One thing I'll just say, if you guys were worried about, if you think NVIDIA, the overhang is off the market, I'll tell you two things that I'd be worried about right now.

16:21Bitcoin, you know, below$85 ,000, the way it sold off, the way it continued today. And the other one's Tesla. It sold off. It was down 10 % at one point yesterday. It was down almost 5 % today. And that just tells you a little bit of some of the extreme risk-taking that has been going on, especially as the AI trade has gone sideways. But those weren't leaders, right? I mean, I hear what you're saying. I think a lot of the losses come from leaders. They're sentiment leaders. Sentiment leaders. Okay. For like FOMO, for risk-on sort of thing. Well, Bitcoin is definitely risk-on, so I agree with that.

16:50When you see this fluff come out of it, and today I think was the biggest outflow. He had a billion dollars coming out of. And last year, let's remember ETFs, 80 percent of the inflows into ETFs were Bitcoin related. I mean, gold. Yes. The pullback in gold. Right. I mean, people are looking to lock in their biggest winners. And for what? For safety. Feels that way. I mean, we've seen a couple of gold sell-offs on the back of broader market sell-offs before. It's not unprecedented. I do think the gold trade is intact. I think Bitcoin is absolutely something to watch. We have talked about it. if the average price of strategies holdings get to the point where Bitcoin is trading, that's going to be problematic.

17:29And the VIX is showing signs of wanting to do something on the upside. Closed low today, I get it, but north of 19 is something to watch. Have we seen a gold pullback? A little bit. What are you talking about? We're 50 bucks from an all-time high. That's a little bit of a lot. After the move we've had, you're calling this a pullback? Don't call this a pullback. Who am I calling this? It's a Rorschach test. All right, coming up, we're dialed into the NVIDIA call. We'll bring you all the headlines as we get them. And there's a lot more earnings action to come. Salesforce, eBay, Paramount, and much more on the move.

18:00The details and numbers out of the quarters straight ahead. But first, a GM jump. Shares driving higher as the company hikes its dividend and kicks off a big buyback program. Can the stocks stay in the fast lane? Don't go anywhere. Fast money is back in tune.

18:20Welcome back to Fast Money. Shares of General Motors getting revved up on news that the company is hiking its quarterly dividend by 25 percent and initiating a$6 billion share buyback, GM ending the day up nearly 4 percent. Our Phil LeBeau joins us with the story. Phil. Melissa, this is not the first time that General Motors has said, you know what, we're coming off of record profits. Let's put that money to use by buying back our shares and increasing the dividends. So here's what the company announced today. As you mentioned,$6 billion stock buyback. By the way,$2 billion of that is part of an accelerated stock retirement program.

18:55So it'll all happen in the second quarter. They're raising the dividend by 25%, jumping it up$0.03 to$0.15 a share. As you take a look at shares of General Motors, keep in mind that the outstanding shares, It's come down by about 400 ,000 shares since the beginning of 2023. That's how many they've retired. They also have an outstanding balance in terms of total shares of about 998 million, maybe a billion shares, roughly speaking, depending on how the share repurchasing is going day to day. So that's a big drop compared to where they were just at the beginning of 23, Melissa. All right, Phil, thanks.

19:35Phil LeBeau on GM. GM? Positive, definitely. I mean, the dividend increase. The bears will say they've got no EV business and that this is a sign of weakness, that this is all they can do with their money. But if you're GM and you have the history that GM has, this is great news. This is a company that's now, you have to give them the benefit of the doubt. We're not talking about one or two quarters. We're talking about four years. Coming out of COVID, this is a company that obviously, and even before COVID, some of these trends were in place, but the profitability we've seen on free cash flow is extraordinary.

20:05This stock should re-rate. I understand that there are headwinds that are going on in the auto space, but this stock should be re-rating and clearly should trade. And again, it is a car company, unlike others that are not. And by the way, they are going to spend more than$8 billion on research and product development. So they're not investing. They're not not investing in their business. $6 billion buyback is not insignificant. A$48 billion company, number one. Number two, the move from$61 down to$45, which we've seen over the last couple months, got us right back to the October low, which is where we took off from, if you recall, in the fall.

20:34So I'm with Tim on this one. If you want to play a little stock market, I think GM has some upside here. But how about the tariffs? March 4th. She's not complaining about them. We only had Farley complain about the tariffs. She seems like she's navigating the seas a lot better than Ford has. And the interesting part of their services business is they have 4.2 subscribers. 4.2 million subscribers. That's not many. Ford has 650 ,000. So when you look at it, it's basically 25 % of the vehicles that can have that service plan that are on the road right now. So if you're going to invest in a car company, GM is definitely over Ford.

21:11Although Ford seems like there could be a dead cow bounce at this because I don't agree with the way that Farley has been running the company. But I'm not a Ford CEO, so I have to just bite my tongue. Everybody's going to, I mean, maybe Ford will feel more of an impact, but everybody will feel an impact of 25 % tariffs. There's no question, and there's no question there were a lot of people running down in Florida that weekend, and there's a lot of people in the auto industry that have been lobbying very hard, and I think there will be a compromise found. I think ultimately U.S. auto, if you think about it, if we're fighting for U.S.

21:42steel, we should be fighting for the big two that are left in Detroit. Good point there. Coming up, we are diving back into tonight's after-hours action. Salesforce, eBay, Paramount, and more, all reporting results, numbers in the quarters next. And speaking of earnings, a major move in the pharma space, Madrigal surging after its Q4 report this morning. The CEO will join us next to dig into the numbers and its latest drug trial data. You're watching Fast Money live from the Nasdaq market site in Times Square. Back right after this.

Read the full transcript

22:16Welcome back to Fast Money. We've got an earnings alert on Salesforce. Shares of the software company dropping after Arizona revenue you miss and like guidance or Seema Modi's got all the numbers. Seema. Melissa, that is the story. Full-year guidance came in short of analyst estimates, raising questions about the return on investment of AgentForce, though regarding its AI agent business, it did end the quarter with 3 ,000 paid customers, up from 200 in the third quarter, given that it only launched this business in October of 2024. Pretty commendable. But on the call, CEO Mark Benioff, once again, excited about what he's hearing from customers, energetic about the growth prospects, saying its AI product line is a multi-billion dollar product line no one, he says, is delivering at this level.

23:01Customers, he says, are telling them that they are light years ahead of others with clients including Equinox, OpenTable, Lennar. He also adds that Salesforce is able to deploy at a really low cost, which has been a point of debate amongst the analyst community. All comes as competition is heating up with Microsoft, feeling a war of words between the two companies over the past few months. CEO Mark Benioff joins Jim Cramer tonight on Mad Money. Melissa. All right, Seema, thanks. Seema Modi with CRM. I mean, the stock was down as much as 10 % after hours on the back of the results initially. Bounced back a little bit.

23:35You got to watch that interview because I don't know if you remember last quarter, Benioff was saying, I think he said something about Microsoft. He was kind of dissing co-pilots. They're all into agents. And he said, go talk to anybody at Microsoft. If they are using co-pilots within Microsoft, that sort of thing. So that's a battle that's going to be fought, obviously, on multiple different levels here. You know, the quarter just wasn't that interesting. The guidance wasn't that interesting. And, you know, at the end of the day, in a market like this, when you're looking for themes where there's going to be adoption that's going to drive the performance as it relates to AI, they're telling a story about the future, not about right now.

24:08But that's good enough for the future. It's just not good enough in the aftermarket right now. I mean, maybe they're sandbagging the full year guidance. It could be. We'll see. I mean, at 30 times earnings, though, you know, the valuation gets in the way. And this stock, if you go back and look, if our crack staff can pull up a chart, I mean, right at the levels that we sort of topped out at in March of last year before we took a leg lower. So this is critical support right here. We'll see what he says on Jim's show, if he assuages any of the concerns. But, you know, it has been and continues to be an expensive name.

24:35If you think that the economy is slowing, and I think the economy is slowing, 49 % of CRM's clients are small businesses. Small businesses have the most front-facing. The headwind for them is the economy. If the economy is slowing, you could see some cracks in his subscriber business. But I do agree with Dan. I think he's entertaining to watch. I think he's got always – you talked about Jensen. He's always got an answer. He's a crowd favorite, but he does it from an antagonistic point of view. So I could see him give something, some fodder. But think about it. The biggest competition he has is Microsoft.

25:12So he has made some acquisitions in the past with Slack that competes with teams. He's had Tableau. I don't even know what Tableau was, but he's been very acquisitory. Yeah. Is that what he bought? I don't know. A table? So if they continue to make acquisitions, that could be another headwind for him. Because if he's got a buy growth in an environment that's slowing, that's a double headwind. Je m 'appelle Timote. Je m 'appelle Guy. Très bien.

25:44I think this was a solid number. I think they've got a new CFO in transition. I think they're going to be conservative. You start talking about FX and leap years and things like that. That's not really what people want to hear with a company like this. But again, I think this was a cautious guide. Can you imagine Tim in high school? Calajatou, that's the one phrase that you walked away with from high school. High school was 40 freaking years ago. More than that. I'm glad I broke this up. Can you imagine Tim in high school French? Oh, with the ladies. With the ladies. With the young ladies. I still remember those three words.

26:16With the mademoiselle. Anyway, coming up, the latest results in drug trial data sending shares of magical pharma surging. But the CEO sees next to the company and the space. That interview when Fast Money returns. Missed a moment of Fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

26:46Welcome back to Fast Money. Stocks closing well off the highs of the regular session. The Dow were racing a 250-point gain early in the day to close down nearly half a percent. The S &P managed to eke out a small gain. It and the Nasdaq both snapping four-day losing streaks. Shares of Supermicro jumping nearly 20 percent after filing delayed financials last night, just in time to meet the Nasdaq's deadline. And check out shares, check out Bitcoin falling into an 82K handle. That was its lowest price since November 11th. And some more after hours movers. eBay beating EPS and revenue expectations, but its first quarter revenue guidance coming in light.

27:22Paramount and Sweetgreen missing on top and bottom lines. And Snowflake and C3AI both topping expectations, but C3AI posting light revenue guidance. Well, Eli Lilly closing at four-month highs after the company announced plans to invest at least$27 billion to build four new U.S. manufacturing sites. Angelica Peebles spoke with CEO David Ricks about the news earlier today. She joins us now with more. Angelica. Hey, Mel. So three of these sites will make active pharmaceutical ingredients, and one will put drugs like ZepBound into pens. Lilly expects them to start making medicine within five years.

27:57Now, this is the latest investment that we've seen from Lilly to increase supply of Zepound and future weight loss drugs. Lilly's CEO, Dave Ricks, told us that cancer and Alzheimer's drugs are also part of this. Now, Lilly's clearly sending a message to the White House. The company made this announcement at an event in D.C. Lawmakers and administration officials were there praising Lilly's investments in the U.S. And Ricks wasn't shy about Lilly's intentions either. We do want to influence the policy environment. And, of course, President Trump and Secretary Lutnik and Kevin Hassett was here today as well.

28:31All can have an influence on that, which is about U.S. tax competitiveness, because none of this would happen if we go back to the days of U.S. having double the tax rate of every other country. We need that corporate tax rate to stay low. And then, of course, other policies that support domestic manufacturing. So on tariffs, Rick said he's speaking with the Trump administration about what the, quote, contours should look like. So we'll have to stay tuned for more on that. Mel? Angelica, I have to ask you about Moderna. We're seeing the shares move lower by about four and a half percent after hours.

29:03There's a headline that just crossed saying that its bird flu shot contract is going to be under review by the Trump administration. How important was that to Moderna? You know, I don't think anyone was expecting it to be a big financial boon. And of course, it would be upside to the company when they really need some upside right now. But this wasn't something that they were actually expecting to take forward, you know, where they factor that into their guidance. So obviously, it's a negative headline, but it's not something that would materially change the results that we're expecting this year.

29:33OK, Angelica, thank you. Angelica Peebles. We were just having a conversation about Lilly yesterday. And most people here were saying Novo over Lilly. Yeah. Well, look, I love I love the attack taken here by the C-suite and really, you know, addressing an important issue has been for pharma companies. And I think they're pretty united on this front. So I think it's great. I think Lilly on valuation is still very compelling. It gets back to whether you think that the type of growth we've seen over the next couple of years equal the addressable market. I do. All right. Meantime, Madrigal Pharmaceuticals surging 15 percent, the stock's best day since November.

30:08The company out with better than expected Q4 results thanks to its MASH fatty liver disease drug Resdifera. Madrigal also posting results of a study in patients whose liver disease is more advanced than the group currently eligible for the drug, saying those patients saw marked improvements in their condition over two years. For more on the results, Madrigal CEO Bill Sibble joins us now. Bill, great to see you again. Thanks for having me back. Can you walk us through Resdifera and the trajectory that you see for the drug going forward, seeing that you're going to be launching in new territories?

30:40Yeah, so first of all, it's been a really great launch. I've launched a lot of blockbuster medicines in my career, and this is the best launch that I've been associated with. In just our third quarter of launch, Q4, we exceeded$100 million, which when you compare against any launch, that is about as good as it gets. So we're really happy with that, and we're making progress along kind of really three key fronts. First of all, number of prescribers. We have continued, we have a target of about 6 ,000 prescribers, and we continue to make progress on a quarterly basis there. We've had 60 % of those prescribers write the product already.

31:24And from a patient perspective, we have now, at the end of December, over 11 ,800 patients on ResDifera, which is a really significant number in itself, crossing the 10 ,000 milestone. And then finally, from a payer perspective, last time I was on, we talked about a very aggressive goal of having 80 % commercial coverage by the end of the year. We did that by the end of the third quarter. So we're on all those metrics tracking very well, which sets us up really for the future. And we have had steady, consistent growth, and we expect the same as we move into 25 and beyond. You mentioned the more than 11 ,000 patients that are already on the drug.

32:08That's actually less than 4 % of market penetration, according to one analyst report I read. How do you view the market and how do GLP-1s fit in? Some will say that it's a competitor drug, in effect, because of its efficacy with MASH. And others will say it's a complement. Yeah, so first of all, I'll say that the market dynamics set up here better than any other opportunity in the industry from my perspective. You mentioned the less than 4 % penetration. that means that we have a long way to go, and that's into the diagnosed 315 ,000 patients that we are focused on. Now, what does competition do?

32:49Actually, competition really helps because it ends up growing the market for you. Every single launch I've been associated with, as you add more products, there's more awareness. Physicians are looking for the disease more, prescribing more, etc. As the market leader in the space with really, I think, the best profile now and as we look into the future, it's almost a holy grail of profiles, a once-a-day pill that's effective and well-tolerated. We're in a really great position. Now, GLP-1s, they are, and they have stated that they will attempt to grow this market. We talk in terms of 315 ,000 patients.

33:28They talk in terms of there being 22 million patients in the U.S., EU5, and Japan. Now, in order for them to really support the business they have, they need to talk about millions of patients. We're very comfortable in the context of the 315 ,000 diagnosed patients. If GLP-1s grow the market like they state they will, we're in a very good position to compete there, especially with the high discontinuation rate that you see with GLP-1s. Novo on a call announced that at the one-year point, about 70 % of patients on Wagovi discontinued. That's an important fact because the study that they ran in MASH was a 72-week trial.

34:15So we look at it that there's a number of paths to victory for us. We're very happy with the 315 ,000 diagnosed patients. But then if this market expands, as we think will happen in the presence of GLP-1s, we're also in a position to win. Bill, great to speak with you. Thank you. Thanks so much for having me. Bill Sibolt, CEO of Madrigal. Guy. Sok, it's a 12-year high today. The loss they reported was much better than expected. Suggests that their path to profitability is a lot faster than people think. Billion dollars of cash and cash equivalents on a$7 billion market cap company. And I think the last time, if I'm not mistaken, we talked about this.

34:52We sort of liked the story. I think you've got to still like the story here, Mel. It's interesting to hear him talk about GLP-1s actually growing their market because you would think on the surface that they would just be competitors to this drug, Rizdifera. No, it seems as if there's a lot of complementary pieces, and some of these companies are actually going to benefit by cooperation, and that's actually going to probably drive some to move even further into our focus. Coming up, AppLovin taking a beating. as short sellers pour cold water on the tech's big run. The slew of critics not loving on the name and where the stock heads from here.

35:25Fast Money is back in two.

35:33Welcome back to Fast Money Software Stock. App 11 plunging today on the back of two short seller reports from Culper Research and Fuzzy Panda. Among allegations of fraud, Fuzzy Panda saying AppLovin illegally tracks children across apps and knowingly serves them explicit ads. They also accused the company of copying Meta's homework, stealing data from the tech giant in how it uses its ad targeting. The Bear Cave, another short seller, made similar allegations last week. AppLovin's CEO refuting some of these claims in a letter to shareholders, saying in part, It's disappointing that a few nefarious short sellers are making false and misleading claims aimed at undermining our success and driving down our stock price for their own financial gain.

36:15Rather than acknowledging the sophisticated AI models our team has built to enhance advertising for our partners. Dan, you're following this move. It's an interesting move. It's interesting to see three come out at the same time. So you've got to wonder if there's some collusion. I mean, I don't love hearing CEOs talk about the targeting in shorts and all that sort of stuff. I mean, I think it's kind of goofy. I think shorting is actually an important part of what goes on in the markets here. But again, you know, sometimes where there's smoke, there's fire. The fact that there's three of them makes some interesting stuff.

36:45It's kind of an easy target when you think about how this stock had rallied over the last year or so and then that gap that it had on earnings. But it's filled in all of that and then some. I just think there's so many other stocks out there that you can play. Like why bother? Yeah. Fuzzy Panda. You said that twice. No, but you said it twice. I enjoyed that. It was in the property. so you read it. You got a kick out of saying that. Do you think, though, if you're fuzzy panda, and again, panda is a bear, right? So I'm just connecting the dots here, so it's a short seller. But do you think he's a nicer short seller?

37:16I think it's supposed to be ironic. I think it's ironic because pandas seem sweet and gentle, and they are being fierce and highlighting alleged fraud. They're not vicious. They eat bamboo and they hang out. They are fun. I think they're cute. Do you have anything on... I had pandas growing up. Do you have anything on the stock market in general? I'll broaden it out. Obviously, it's up 461 % for the last year, but I think it's going to bring up a big dialogue over what AI can you steal. It's going to, not necessarily for this stock in particular, but for the group as a whole, we're going to find out what's out there in the public domain.

37:55Did they really steal something? Was it nefarious or was it just open? And what is AI? One of the allegations is that their AI product, Axon 2.0, is not really AI, and it's all sort of smoke and mirrors just to get clients, basically. Fifteen times revenue with or without fuzzy bears. Fuzzy bear? How about fuzzy bear? Fuzzy bear. Fuzzy bear. Fuzzy bear is a different kind of bear. Stop being hutch. Anyway, coming up, a pair of fast movers catching our attention, why Bud was bubbling higher in the latest out of U.S. Steel's merger drama. That is next. More Fast Money in two.

38:36Welcome back to Fast Money. Another check on NVIDIA shares. They're up by about a percent plus percent here. The call is still underway. Chris Rowland is back to give us all the key headlines here. Chris, anything notable? Yeah, no. Jensen's really just talking about AI continuing into the future, defending scaling laws, talking about next generation products. It does appear as those are on time, both GB200 and GB300, and then hinting at new products coming at GTC, which we will have in a couple of weeks. What do you make of the stock's reaction? We were up 4 % in the regular session, just about, or up a percent after hours, 53 minutes into the call.

39:24Yeah, this really seems like an in-line result and guide quarter and no major announcements, no major setbacks or pull forwards in the roadmap. So this is actually kind of the response I would have expected. Okay. Chris, thanks. Chris Rollins of Susquehanna with the latest on the conference call. Is this enough to move the stock out of that rut that you're highlighting, the nine-month rut? Or does it just keep meandering? I don't think so. I think there has to be some sort of, you know, kind of adoption story that plays out in other industries that suggests that this is going to be something that we can start to model out going forward.

40:07And I think that this open source thing is really interesting because, again, it might not be such a negative as was perceived a few weeks ago. And it might actually drive down the cost to compute, which will actually kind of get adoption going sooner than expected. But there's nothing here there to kind of give to the bulls or the bears, in my opinion. All right. Let's get to today's movers here. AB InBev popping over 7 % as Q4 revenue beat despite declining volumes. The Budweiser maker seeing weak demand in China and Argentina, though the CEO said he expects recovery this year. So, Tim, what do you make of this?

40:39Very low bar. Interesting valuation. Remember, this is not your America. This is not your Clydesdale anymore. This is actually not an American company. The Ford valuation, not all that attractive. I think if you look at where this company has come from and also the consolidation in the beer market, I actually think this is a pretty good space to own it. I also think it's the market to own it. I think they will be buying back stock as well. All right. Let's take a look at U.S. Steel shares slipping amid confusion over the status of its acquisition by Nippon Steel. According to reports, the Japanese company planning to meet with U.S.

41:09officials to revive a deal. That conflicts with President Trump's claims that Nippon plans to invest in U.S. steel instead of purchasing it. Steve, you're long, X. I am. I got longer today. I think that ultimately this is another barometer for President Trump's success. So he has the stock market, then it turned into Bitcoin or crypto, and now it's steel. And I think he would fail if he if this doesn't perform or outperform. I think that will be a failure that he would take personally. So I think the stock goes higher in an overwhelmingly amount of different possibilities. All right. Up next, final trades.

41:54We are very excited. Yeah. Very special. Fast Money Live tomorrow, 5 p.m. Eastern Time. We'll have a super-sized desk and over 100 diehard fans from over 30 states and three countries. You will not want to miss this. It's going to be something. They don't know what they're getting themselves into. We don't either. This is going to be awesome. We don't either. Time for the final trade, Tim. I think you know what you're getting yourself into if you buy GM at Guy's 46 level. I think you're getting long here. Steve. Steel, letter X, trades at$38 right now. That Nippon deal was$55. I think it works its way back to that level.

42:27Daniel. Guy, what's the Fed's most favored inflation? The PCE. Oh, that's Friday morning. I think yield's probably moved back higher. Is he in trouble? That'll be a seller of the TLT. Because I call him Daniel? You call him Daniel. You're in trouble. I wanted to try it on. Guy. 30 states would be 60 % of the states available. It's really amazing how far. Dublin, Alaska, Hawaii. International, yeah. It's crazy. We're psyched. I do, Melissa. Good. And I'm happy you're feeling better. Boyd Gaming. All right. Excellent. See you tomorrow. Mad Money starts right now.

43:26Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money disclaimer, please visit cnbc.com forward slash Fast Money disclaimer.

From the publisher

Shares of Nvidia on the move after reporting its latest results. How the Fast Money traders are handling the semi giant, and the impact it has on the broader market. Plus Madrigal Pharma surging on the back of results. The latest drug data pushing that name higher, and what the CEO has to say about the company’s next move.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Nvidia Reports Results… And A Big Move In The Pharma Space 2/26/25CNBC's "Fast Money" · 44 min
Listen in VO